| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s, challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications.
The retrospective analysis included 816 members in Omada's GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months. At one year post-discontinuation members showed just 0.8% average weight change, compared to 11-12% weight gain typically seen in clinical trials where participants do not always have access to wraparound lifestyle support after they stop the medication. Omada's analysis demonstrated participants largely experienced weight maintenance consistently throughout the year, with 0.03% average weight change at 6 months and 0.6% average weight change at 9 months,1 suggesting the sustained impact of lifestyle support at this critical moment in their GLP-1 journey.
Posted In: OMDA
